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Glomerular Endothelial Dysfunction,
Altered Hemorheology and Hemodynamic Maladjustment in
Nephrosis with Focal Segmental Glomerulosclerosis
Narisa Futrakul, Visith Sitprija,1 Prasong Siriviriyakul, Prasit Futrakul1
Oxidative stress and a defective immunocirculatory balance induce glomerular endothelial cell (GEC)
dysfunction, which is expressed as proteinuria and altered hemorheology, namely blood hypercoagulability,
blood hyperviscosity, and local intravascular coagulation in severe nephrosis. In addition, defective release of
endothelium-dependent vasodilators in conjunction with enhanced production of vasoconstrictors induces
hemodynamic maladjustment by preferential constriction at the efferent arteriole. Such constriction has three
significant hemodynamic impacts. Proximal to the efferent arteriolar constriction, it induces an overestimated
glomerular filtration rate due to hyperfiltration, and an elevated intraglomerular hydrostatic pressure. Distal to
the efferent arteriolar constriction, it exaggeratedly reduces the peritubular capillary flow. Such hemodynamic
maladjustment causes over-distension of the glomerular capillary, detaching the podocyte from the basement
membrane. Podocyte injury decreases the production of vascular endothelial growth factor, thereby aggravating
the GEC injury. Increased GEC injury further aggravates the hemodynamic maladjustment, the podocyte
injury, and eventually the GEC injury, in a vicious cycle. Sustained ischemic injury activates the profibrogenic
pathway and eventually culminates in tubulointerstitial fibrosis. In accordance with this concept, correction of
hemodynamic maladjustment with vasodilators and of altered hemorheology with antiplatelet drugs and
anticoagulation will improve renal hemodynamics and function, and prevent the progression of renal disease.
[Hong Kong J Nephrol 2004;6(2):69–73]
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INTRODUCTION
Two crucial issues that need to be addressed in ne-
phrosis associated with focal segmental glomerulo-
sclerosis (FSGS) are the proteinuria, which is mainly
steroid resistant, and the mechanism of nephronal
damage, namely tubulointerstitial fibrosis (TIF) and
glomerulosclerosis. There is much evidence that ab-
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normal T cell function induces proteinuria in both the
human clinical setting and in animal models. Plasma
from nephrotic patients contains a vascular perme-
ability factor derived from T cells. Within this context,
there is increased Th1 proinflammatory cytokine ac-
tivity, namely tumor necrosis factor alpha, interleu-
kin (IL)-2, IL-8, IL-12, IL-15, and IL-18 [1–6]. In
minimal-change disease or mesangial proliferative
nephrosis, the anti-inflammatory cytokine (IL-10) of
the Th2 pathway is also usually elevated. However,
in nephrosis with FSGS, there is defective release of
anti-inflammatory cytokines [3,4].
Experimental studies indicate that during relapse
of minimal-change nephrosis, nuclear extracts from
peripheral blood mononuclear cells display high lev-
els of nuclear factor kappa B (NF-gB) DNA-binding
activity, consisting primarily of p50/Rel A (p65) com-
plexes [7]. The lack of expression of I-gB alpha pro-
tein is associated with down-regulation of I-gB alpha
mRNA, and increases in the levels of mRNA encoding
the preteose alpha 2 subunit in the proteolytic path-
way. Stimulation of the NF-gB pathway is believed
to be triggered by infection, toxin, lipid, or reactive
oxygen species. Enhanced reactive oxygen species
in conjunction with defective antioxidants have been
demonstrated in both mild and severe forms of
nephrosis [8].
GLOMERULAR ENDOTHELIAL DYSFUNCTION
Injury to the glomerular endothelial cell (GEC) induces
loss of negative surface charge, which enhances pro-
teinuria and procoagulant activity [9]. Procoagulant
activity is characterized by the presence of blood hy-
percoagulability, shortened platelet half-life and fibrin-
ogen half-life, blood hyperviscosity, fibrin deposit in
the kidney, elevated levels of fibrin degradation pro-
ducts in the serum and urine, and altered hemorheo-
logy of erythrocytes during active proteinuria [10–
19]. In addition, there is defective release of vasodila-
tors in the dysfunctional GEC and, at the same time,
enhanced release of vasoconstrictors, namely angioten-
sin II, endothelin, and thromboxane A2. A mild degree
of such a provasoconstrictive state is observed in
nephrosis associated with mesangial proliferation
(MesP), which is reflected by a mild reduction in renal
plasma flow (RPF) and a mild elevation in arteriolar
resistance [20]. However, in severe nephrosis such as
FSGS, a greater magnitude of intrarenal hemodynamic
abnormality is observed, which is characterized by a
greater reduction in RPF and peritubular capillary flow
(PTCF), a greater increase in afferent and efferent
arteriolar resistance, and elevated intraglomerular
hydrostatic pressure (PG) [21,22]. An in vitro study has
recently demonstrated that sera from nephrotic patients
can induce endothelial cell cytotoxicity [23]. Sera from
patients with MesP nephrosis increased endothelial
cell cytotoxicity to 18 ( 9%, compared with 1.8 (
0.8% with control sera, whereas sera from patients
with nephrosis associated with FSGS increased en-
dothelial cell cytotoxicity to 40 ( 9%. Such an endo-
thelial cell cytotoxicity test in vitro correlates with
GEC dysfunction in vivo, as determined by intrare-
nal hemodynamic study [23].
HEMODYNAMIC MALADJUSTMENT
In severe nephrosis such as FSGS and MesP nephrosis
associated with TIF, elevated vasoconstrictors in the
presence of defective release of vasodilators induces
hemodynamic maladjustment by preferentially con-
stricting the efferent arteriole. Such a constriction has
three significant hemodynamic impacts. First, proxi-
mal to the efferent arteriolar constriction, it induces
an overestimated glomerular filtration rate due to
hyperfiltration. Second, it causes an elevated PG due
to the higher blood inflow and lower blood outflow.
Intraglomerular hypertension in conjunction with
defective blood quality, altered hemorheology, en-
hanced proinflammatory activity, and renal hypo-
perfusion culminates in the development of glomer-
ulosclerosis. Third, distal to the efferent arteriolar
constriction, it exaggeratedly reduces the PTCF sup-
plying the tubulointerstitium (Figure 1).
Increased PG distends the glomerular capillary loop,
thereby detaching the podocyte from the basement
membrane. Increased podocyte injury in this manner,
in conjunction with toxic injury from reactive oxygen
species and proinflammatory cytokines, decreases
the production of vascular endothelial growth factor
(VEGF), which is essential to the survival and regen-
eration of the endothelial cell. Both Kriz and associ-
ates [24] and Rennke [25] have elegantly demon-
strated podocyte injury by detachment from the base-
ment membrane secondary to ballooning of the cap-
illary loop in nephrosis with FSGS. Mild reduction in
the level of VEGF mRNA and its receptor (flk-1)
mRNA was transiently documented in the first week
following injection of puromycin aminonucleoside to
induce nephrosis [26]. However, permanent loss of
podocyte function, with impaired production and
release of VEGF, is likely in nephrosis with FSGS.
Defective release of VEGF, leading to impaired an-
giogenesis, is correlated with progressive renal disease
[27,28]. A decrease in VEGF and flk-1 renders the en-
dothelial cell apoptotic or cytotoxic. Histochemical
staining for glomerular endothelial factor VIII and
postglomerular endothelial factor VIII has demon-
strated a greater loss of endothelial cells in the renal
microcirculation in nephrosis with FSGS than in MesP
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nephrosis [29]. Thus, injury to the GEC is enhanced
and aggravates hemodynamic maladjustment and
injury to the podocyte, eventually causing further
injury to the GEC and post GEC in the renal micro-
circulation, in a vicious cycle. Finally, sustained ische-
mic injury to the PTCF, which activates the profi-
brogenic pathway, culminates in the development of
TIF [30–35]. The significance of reductions in PTCF
in relation to the development of TIF has been demon-
strated by multiple regression analysis, which revealed
that reductions in PTCF correlate inversely with the
development of TIF. This means that the lower the
reduction in PTCF, the greater the magnitude of
TIF. Furthermore, reduction in PTCF precedes the
development of TIF, which supports this cause-and-
effect relationship [36].
In accordance with the preceding concept of GEC
dysfunction induced by oxidative stress and immuno-
circulatory disturbance, such toxic triggers affect the
podocyte and induce podocyte dysfunction or injury.
Podocyte injury with structural damage such as podo-
cytopenia and nephrin loss is believed to be associ-
ated with proteinuria [37]. A synergistic interaction
between injury to the glomerular endothelium and
podocyte amplifies the vicious cycle that eventual-
ly leads to progressive reduction in renal perfusion
and increase in the magnitude of proteinuria (Fig-
ure 1).
THERAPEUTIC STRATEGY TO PREVENT RENAL
DISEASE PROGRESSION
The magnitude of GEC dysfunction and its effect on
hemodynamic maladjustment is likely to determine
the severity of disease and the magnitude of TIF in se-
vere nephrosis. A therapeutic intervention to correct
the hemodynamic maladjustment and restore GEC
function would be welcome. Indeed, treatment with
vasodilators, including angiotensin converting enzyme
inhibitors (ACEIs), angiotensin II type 1 receptor an-
tagonists (AIIRAs), and calcium-channel blockers, can
improve renal perfusion and decrease PG to normal
(Figure 2) [38–42]. In practice, a combination of vaso-
dilators is recommended, and the doses needed to
correct hemodynamic maladjustment are more than
those needed for blood-pressure reduction. Blood-
pressure reduction is usually achieved much earlier
than conversion of renal arteriolar resistance to nor-
mal. Altered hemorheology can be corrected by anti-
platelet and anticoagulant therapy [10,11,44,45].
Antioxidant therapy with high doses of vitamin C
(1,000–3,000 mg/day) and vitamin E (800 units/day)
restores GEC function and suppresses endothelial cell
cytotoxicity [8,45–48].
If persistent proteinuria is encountered in nephrosis
with FSGS following vasodilator treatment, treatment
with Ganoderma lucidum (750 mg/day) can suppress
steroid-resistant proteinuria [49].
These therapeutic strategies have resulted in im-
provements in renal hemodynamics and renal func-
tion. There is substantial increase in creatinine clear-
Figure 1. Pathogenetic mechanism of renal disease progression in
severe nephrosis. AII = angiotensin II; ET = endothelin; LIC = local
intravascular coagulation; MMPI = matrix metalloproteinase
inhibitor; PAI = plasminogen activator inhibitor; PTCF = peritubular
capillary flow; RA = afferent arteriolar resistance; RE = efferent
arteriolar resistance; ROS = reactive oxygen species; RPF = renal
plasma flow; TGFB = transforming growth factor beta; Th = T helper;
TXA2 = thromboxane A2; VEGF = vascular endothelial growth
factor.
Figure 2. Correction of hemodynamic maladjustment with vaso-
dilators: pre- and post-treatment intrarenal hemodynamic study
in nephrotic patients with focal segmental glomerulosclerosis
treated with angiotensin converting-enzyme inhibitor, angioten-
sin II receptor antagonist, calcium-channel blocker, and antiplate-
let agent in accordance with the dose described previously [43].
RA = afferent arteriolar resistance; RE = efferent arteriolar resis-
tance; PG = intraglomerular hydrostatic pressure; RPF = renal
plasma flow; PTCF = peritubular capillary flow; GFR = glomer-
ular filtration rate.
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ance and a decline in the fractional excretion of mag-
nesium (FE Mg) in severe nephrosis with FSGS [8,
49]. Inasmuch as the FE Mg correlates directly with
the magnitude of TIF [50] and inversely with the
reduction in PTCF [51], improvement in FE Mg
following treatment implies that the inflammatory
process in the tubulointerstitium is likely to be sup-
pressed. In this regard, it has recently been demon-
strated that a combination of an ACEI and an AIIRA
can diminish kidney tissue angiotensin II levels, and
that regression of kidney disease can be accom-
plished in animal models [52,53].
REFERENCES
1. Laflam PF, Haraguchi S, Garin EH. Cytokine mRNA profile in
lipoid nephrosis: evidence for increased IL-18 mRNA stability.
Nephron 2002;91:620–6.
2. Matsumoto K, Kanmatsuse K. Augmented interleukin-18 produc-
tion by peripheral monocytes in patients with minimal-change
nephrotic syndrome. Am J Nephrol 2001;21:20–7.
3. Futrakul N, Butthep P, Patumraj S, Tipprukmas N, Futrakul P.
Enhanced tumor necrosis factor in the serum and renal hypoper-
fusion in nephrosis associated with focal segmental glomerulo-
sclerosis. Ren Fail 2000;22:213–7.
4. Lama G, Luongo I, Tirino G, Borriello A, Carangio C, Salsano
ME. T-lymphocyte populations and cytokines in childhood
nephrotic syndrome. Am J Kidney Dis 2002;39:958–65.
5. Matsumoto K, Kanmatsuse K. Interleukin-18 and interleukin-12
synergize to stimulate the production of vascular permeability
factor by T-lymphocytes in normal subjects and in patients with
minimal-change nephrotic syndrome. Nephron 2000;85:127–33.
6. Matsumoto K, Kanmatsuse K. Interleukin-15 and interleukin-12
have an additive effect on the release of vascular permeability
factor by peripheral blood mononuclear cells in normals and in
patients with nephrotic syndrome. Clin Nephrol 1999; 52:8–10.
7. Sahali D, Pawlak A, Le-Gouvello S, Lang P, Valanciute A, Remy
P, et al. Transcriptional and post-transcriptional alterations of
IkappaBalpha in active minimal-change nephrotic syndrome. J
Am Soc Nephrol 2001;12:1648–58.
8. Futrakul N, Tosukhowong P, Valyapongpichit Y, Tipprukmas N,
Futrakul P, Patumraj S. Oxidative stress and hemodynamic mal-
adjustment in chronic renal disease: a therapeutic implication. Ren
Fail 2002;24:433–45.
9. Naga M, Honda N, Yoshitoshi Y. Effect of dipyridamole on glo-
merular negative charge in nephrotic rats induced by amino-
nucleoside. VIII International Congress of Nephrology, Athens,
June 1981, Abstract book:239.
10. Futrakul P, Poshyachinda M, Mitrakul C. Hypercoagulability in
the nephrotic syndrome: use of anticoagulant. In: Zurukzoglu
W, Papadimitrio M, Pyrpasopoulos M, Sion M, Zamboulis C
(eds). Advances in Basic Nephrology: Proceedings of the 8th
International Congress of Nephrology, Athens. Basel: Karger,
1981:297–301.
11. Futrakul P, Poshyachinda M, Mitrakul C. Focal sclerosing
glomerulonephritis: a kinetic evaluation of hemostasis and the
effect of anticoagulant therapy: a controlled study. Clin Nephrol
1978;10:180–6.
12. Adhikari M, Coovadia HM, Greig HB, Christensen S. Factor VIII
procoagulant activity in children with nephrotic syndrome and
poststreptococcal glomerulonephritis. Nephron 1978;22:301–5.
13. Llach F. Hypercoagulability, renal vein thrombosis and other
thrombotic complications of nephrotic syndrome. Kidney Int 1985;
28:429–39.
14. Futrakul P, Poshyachinda V, Poshyachinda M, Sitprija V, Mitrakul
C, Kankeerati V. Nephrotic syndrome: a kinetic evaluation of hemo-
stasis and anticoagulant therapy in children. J Med Assoc Thai
1978;61:309–18.
15. Duffy JL, Cinque T, Grishman E, Churg J. Intraglomerular fibrin,
platelet aggregation and subendothelial deposit in lipoid nephro-
sis. J Clin Invest 1970;49:251–6.
16. Futrakul P, Surichamorn P, Cherdboonchart V. Serum and urinary
fibrin degradation product in Thai renal patients. J Med Assoc
Thai 1974;57:346–50.
17. Stiehm ER, Kuplic LS, Nehling DT. Urinary fibrin split products
in human renal disease. J Lab Clin Med 1971;77:843–7.
18. Cechin E, De Marchi S, Panarello G, De Augelio V. Rheological
abnormalities of erythrocyte deformability and increased glycosy-
lation of hemoglobin in the nephrotic syndrome. Am J Nephrol
1987;7:18–21.
19. Zwaginga JJ, Koomans HA, Sixma JJ, Rabelink AJ. Thrombus
formation and platelet vessel wall interaction in the nephrotic
syndrome and flow conditions. J Clin Invest 1994;93:204–11.
20. Futrakul N, Futrakul P, Poshyachinda M, Apaiwong S, Sensiriva-
tana R, Thamaree S, et al. Intrarenal hemodynamic alteration in
mesangial proliferative nephrotic syndrome with steroid resis-
tance: effects of vasodilators. Nephron 1994;66:366–7.
21. Futrakul P, Sitprija V, Yenrudi S, Poshyachinda M, Sensirivatana
R, Watana D, et al. Glomerular endothelial dysfunction deter-
mines disease progression: a hypothesis. Am J Nephrol 1997;17:
533–40.
22. Futrakul P, Poshyachinda M, Yenrudi S, Saleekul P, Sensirivatana
R, Futrakul N, et al. Intrarenal hemodynamic abnormality in se-
vere form of glomerulonephritis: therapeutic benefit with vaso-
dilators. J Med Assoc Thai 1992;75:375–85.
23. Futrakul N, Panichakul T, Chaisuriya P, Sirisinha S, Patumraj S,
Futrakul P. Endothelial cell cytotoxicity and renal hypoperfusion
in idiopathic nephrotic syndrome. Nephron 2000;86:241–2.
24. Kriz W, Elger M, Nagata M, Kretzler M, Uiker S, Koeppen-
Hageman I, et al. The role of podocytes in the development of
glomerulosclerosis. Kidney Int Suppl 1994;45:64–72.
25. Rennke HG. How does glomerular epithelial cell injury contribute
to progressive glomerular damage? Kidney Int Suppl 1994;45:
58–63.
26. Fan L, Wakayama T, Yokoyama S, Amano O, Iseki S. Downregu-
lation of vascular endothelial growth factor and its receptors in
the kidney in rats with puromycin aminonucleoside nephrosis.
Nephron 2002;90:95–102.
27. Kang DH, Kanellis J, Hugo C, Truong L, Anderson S, Kerjaschki
D, et al. Role of microvascular endothelium in progressive renal
disease. J Am Soc Nephrol 2002;13:806–16.
28. Kang DH, Joly AH, Oh SE, Hugo C, Kerjaschki D, Gordon KL,
et al. Impaired angiogenesis in the remnant kidney model: I.
Potential role of vascular endothelial growth factor and throm-
bospondin-1. J Am Soc Nephrol 2001;12:1434–47.
29. Futrakul N, Kittikowit W, Yenrudi S. Reduced endothelial factor
VIII staining in renal microcirculation correlates with hemody-
namic alteration in nephrosis. Ren Fail 2003;25:759–64.
30. Wei Z, Costa K, Al-Medhi AB, Dodia C, Muzykantor V, Fisher
AB. Simulated ischemia in flow-adapted endothelial cells leads
Hong Kong J Nephrol • October 2004 • Vol 6 • No 2 73
Nephrosis with focal segmental glomerulosclerosis
to generation of reactive oxygen species and cell signaling. Circ
Res 1999;85:682–9.
31. Malek AM, Gibbons GH, Dzau VJ, Izumo S. Fluid shear stress
differentially modulates expression of gene encoding basic
fibroblast growth factor and platelet derived growth factor B-chain
in vascular endothelium. J Clin Invest 1993;92:2013–21.
32. Nagel T, Resnick N, Atkinson WJ, Dewey CF, Gimbrone MA Jr.
Shear stress upregulates functional ICAM-1 expression in cultured
vascular endothelial cells. FASEB J 1993;7:A2. (Abstract)
33. Malek AM, Izumo J. Molecular aspects of signal transduction of
shear stress in the endothelial cell. J Hypertens 1994;12:989–1000.
34. Frangos JA, Estain SG, McIntire LV, Ives CL. Flow effects on
prostacyclin production by cultured human endothelial cells.
Science 1984;227:1477–9.
35. Bottinger EP, Bitzer M. TGF-beta signaling in renal disease. J
Am Soc Nephrol 2002;13:2600–10.
36. Futrakul N, Yenrudi S, Sensirivatana R, Watana D, Laohapaibul
A, Watanapenphaibul K, et al. Peritubular capillary flow deter-
mines tubulointerstitial disease in idiopathic nephrotic syndrome.
Ren Fail 2000;22:329–35.
37. Fogo A. Nephrotic syndrome: molecular and genetic basis.
Nephron 2000;85:8–13.
38. Futrakul P, Futrakul N, Sitprija V. Enhanced renal perfusion
improves function in severe nephrosis with focal segmental
glomerulosclerosis. Nephrology 1994;1:51–7.
39. Marinides GN, Grogged GC, Cohen AH, Border WA. Enalapril
and low protein reverse chronic puromycin aminonucleoside
nephropathy. Kidney Int 1990;37:749–57.
40. Anderson S, Rennke HG, Brenner BM. Therapeutic advantage of
converting enzyme inhibitors arresting progressive renal disease
associated with systemic hypertension in the rat. J Clin Invest
1986;77:1993–2000.
41. Stefanski A, Amann K, Ritz E. To prevent progression: ACE
inhibitors, calcium antagonists or both? Nephrol Dial Transplant
1995;10:151–2.
42. Remuzzi A, Benigni A, Malanchini B, Bruzzi I, Foglieni C, Re-
muzzi G. ACE inhibition prevents renal failure and death in uni-
nephrectomized MWF/Ztm rats. Kidney Int 1995;47:1319–26.
43. Futrakul N, Boonyen M, Patumraj S, Siriviriyakul P, Tosukho-
wong P, Futrakul P. Treatment of glomerular endothelial dys-
function in steroid-resistant nephrosis with Ganoderma lucidum,
vitamins C, E and vasodilators. Clin Hemorheol Microcirc 2003;
29:205–10.
44. Ito S, Yasaki T. Effect of dipyridamole treatment on proteinuria
in pediatric renal disease. Nephron 1980;44:174–9.
45. Woo KT, Whitworth JA, Kincaid-Smith P. Effect of antiplatelet
agents on circulating platelet aggregates in patients with glomer-
ulonephritis. Thromb Res 1980;20:663–8.
46. Taddei S, Virdis A, Ghiadoni L, Magagna A, Salvetti A. Vitamin
C improves endothelium dependent vasodilation by restoring ni-
tric oxide activity in essential hypertension. Circulation 1998;97:
2222–9.
47. Lee HS, Jeong JY, Kim BC, Kim YS, Zhang YZ, Chung HK.
Dietary antioxidant inhibits lipoprotein oxidation and renal injury
in experimental focal segmental glomerulosclerosis. Kidney Int
1997;51:1151–9.
48. Trachtman H, Schwob N, Maesaka J, Valderrama E. Dietary vita-
min E supplementation ameliorates renal injury in chronic puro-
mycin aminonucleoside nephropathy. J Am Soc Nephrol 1995;5:
1811–9.
49. Futrakul N, Boongen M, Tosukhowong P, Patumraj S, Futrakul P.
Treatment with vasodilators and crude extract of Ganoderma
lucidum suppresses proteinuria in nephrosis with focal segmental
glomerulosclerosis. Nephron 2002;92:719–20.
50. Futrakul P, Yenrudi S, Futrakul N, Sensirivatana R, Kingwatanakul
P, Jungthirapanich J, et al. Tubular function and tubulointerstitial
disease. Am J Kidney Dis 1999;33:886–91.
51. Futrakul N, Yenrudi S, Sensirivatana R, Cherdkiadtikul T, Lao-
hapaibul A, Futrakul S, et al. Peritubular capillary flow and tu-
bular function in idiopathic nephrotic syndrome. Nephron 2000;
85:181–2.
52. Komine N, Khang S, Wead LM, Blantz RC, Gabbar FB. Effect of
combining an ACE inhibitor and an angiotensin II receptor blocker
on plasma and kidney tissue angiotensin II levels. Am J Kidney
Dis 2002;39:159–64.
53. Remuzzi A, Gagliardini E, Donadino C, Fassi A, Sangalli F, Lepre
MS, et al. Effect of angiotensin II antagonism on the regression
of kidney disease in the rat. Kidney Int 2002;62:885–94.
